1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Weiss, M.A. Hua, Q.X. Chu, Y.C. Jia, W. Philips, N.F. Wang, R.Y. Katsoyannis, P.G. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US J.Biol.Chem. JBCHA3 0071 0021-9258 277 43443 43453 10.1074/jbc.M206107200 12196530 Mechanism of insulin chain combination. Asymmetric roles of A-chain alpha-helices in disulfide pairing 2002 10.2210/pdb1lkq/pdb pdb_00001lkq 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 INSULIN A CHAIN (RESIDUES 90-110) 2285.513 INSULIN I2G,V3G 1 syn polymer INSULIN B CHAIN (RESIDUES 25-54) 3410.894 INSULIN H10D,P28K,K29P 1 syn polymer no no GGGEQCCTSICSLYQLENYCN GGGEQCCTSICSLYQLENYCN A polypeptide(L) no no FVNQHLCGSDLVEALYLVCGERGFFYTKPT FVNQHLCGSDLVEALYLVCGERGFFYTKPT B polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n database_2 pdbx_struct_assembly pdbx_struct_oper_list struct_ref_seq_dif repository Initial release Version format compliance Version format compliance Database references Derived calculations 1 0 2002-05-22 1 1 2008-04-28 1 2 2011-07-13 1 3 2021-10-27 _database_2.pdbx_DOI _database_2.pdbx_database_accession _struct_ref_seq_dif.details RCSB Y RCSB 2002-04-25 REL REL THE PEPTIDE WAS CHEMICALLY SYNTHESIZED. THE SEQUENCE OF THE PEPTIDE IS NATURALLY FOUND IN HOMO SAPIENS (HUMAN). sample THE PEPTIDE WAS CHEMICALLY SYNTHESIZED. THE SEQUENCE OF THE PEPTIDE IS NATURALLY FOUND IN HOMO SAPIENS (HUMAN). sample THIS STRUCTURE WAS DETERMINED USING STANDARD 2D HOMONUCLEAR TECHNIQUES. structures with the lowest energy 35 20 2D NOESY TOCSY 7.00 AMBIENT 298.00 K THE STRUCTURE IS BASED ON A TOTAL OF 390 RESTRAINTS, 325 ARE NOE-DERIVED DISTANCE CONSTRAINTS, 31 DIHEDRAL ANGLE RESTRAINTS, 34 DISTANCE RESTRAINTS FROM HYDROGEN BONDS. DISTANCE GEOMETRY AND SIMULATED ANNEALING 1 1.0 MM GLYA2,A3-DKP- INSULIN; 90% H2O/10% D2O; BRUNGER (X-PLOR), MOLECULAR SIMULATIONS INC. (DGII) refinement X-PLOR 3.85, DGII INSIGHTII 2000 structure solution VNMR 6.1B 600 Varian INOVA GLY 1 n 1 GLY 1 A GLY 2 n 2 GLY 2 A GLY 3 n 3 GLY 3 A GLU 4 n 4 GLU 4 A GLN 5 n 5 GLN 5 A CYS 6 n 6 CYS 6 A CYS 7 n 7 CYS 7 A THR 8 n 8 THR 8 A SER 9 n 9 SER 9 A ILE 10 n 10 ILE 10 A CYS 11 n 11 CYS 11 A SER 12 n 12 SER 12 A LEU 13 n 13 LEU 13 A TYR 14 n 14 TYR 14 A GLN 15 n 15 GLN 15 A LEU 16 n 16 LEU 16 A GLU 17 n 17 GLU 17 A ASN 18 n 18 ASN 18 A TYR 19 n 19 TYR 19 A CYS 20 n 20 CYS 20 A ASN 21 n 21 ASN 21 A PHE 1 n 1 PHE 1 B VAL 2 n 2 VAL 2 B ASN 3 n 3 ASN 3 B GLN 4 n 4 GLN 4 B HIS 5 n 5 HIS 5 B LEU 6 n 6 LEU 6 B CYS 7 n 7 CYS 7 B GLY 8 n 8 GLY 8 B SER 9 n 9 SER 9 B ASP 10 n 10 ASP 10 B LEU 11 n 11 LEU 11 B VAL 12 n 12 VAL 12 B GLU 13 n 13 GLU 13 B ALA 14 n 14 ALA 14 B LEU 15 n 15 LEU 15 B TYR 16 n 16 TYR 16 B LEU 17 n 17 LEU 17 B VAL 18 n 18 VAL 18 B CYS 19 n 19 CYS 19 B GLY 20 n 20 GLY 20 B GLU 21 n 21 GLU 21 B ARG 22 n 22 ARG 22 B GLY 23 n 23 GLY 23 B PHE 24 n 24 PHE 24 B PHE 25 n 25 PHE 25 B TYR 26 n 26 TYR 26 B THR 27 n 27 THR 27 B LYS 28 n 28 LYS 28 B PRO 29 n 29 PRO 29 B THR 30 n 30 THR 30 B author_defined_assembly 2 dimeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 2 B B O H VAL TYR 12 16 1.45 3 B B O H CYS GLU 19 21 1.54 4 B B O H VAL TYR 12 16 1.55 6 A A O H SER LEU 12 16 1.57 8 B B O H VAL TYR 12 16 1.44 9 B B O H VAL TYR 12 16 1.45 9 A A H OE1 SER GLN 12 15 1.51 11 B B O H CYS GLU 19 21 1.56 14 B B O H CYS LEU 7 11 1.59 17 B B O H SER VAL 9 12 1.55 18 B B O H CYS GLU 19 21 1.54 18 B B O H VAL TYR 12 16 1.55 20 B B O H VAL TYR 12 16 1.43 20 B B O H SER VAL 9 12 1.54 1 B ARG 22 0.317 SIDE CHAIN 2 B ARG 22 0.300 SIDE CHAIN 3 B ARG 22 0.289 SIDE CHAIN 4 B ARG 22 0.276 SIDE CHAIN 5 B ARG 22 0.275 SIDE CHAIN 6 B ARG 22 0.300 SIDE CHAIN 7 B ARG 22 0.316 SIDE CHAIN 8 B ARG 22 0.184 SIDE CHAIN 9 B ARG 22 0.229 SIDE CHAIN 10 B ARG 22 0.148 SIDE CHAIN 11 B ARG 22 0.152 SIDE CHAIN 12 B ARG 22 0.304 SIDE CHAIN 13 B ARG 22 0.211 SIDE CHAIN 14 B ARG 22 0.219 SIDE CHAIN 15 B ARG 22 0.272 SIDE CHAIN 16 B ARG 22 0.316 SIDE CHAIN 17 B ARG 22 0.225 SIDE CHAIN 18 B ARG 22 0.176 SIDE CHAIN 20 B ARG 22 0.276 SIDE CHAIN 1 A GLN 5 -143.77 -30.89 1 A CYS 7 -100.99 -78.21 1 A SER 9 -100.59 -161.33 1 A CYS 11 -106.56 -164.62 1 B VAL 2 -79.44 -159.94 1 B PHE 24 159.32 143.59 1 B THR 27 -91.88 -123.16 2 A GLU 4 -81.22 -151.10 2 A GLN 5 69.78 127.28 2 B VAL 2 -161.63 -160.22 2 B HIS 5 -165.37 109.14 2 B ARG 22 159.95 -28.70 2 B PHE 24 174.48 118.41 2 B PHE 25 -109.50 78.28 2 B TYR 26 165.86 112.03 2 B PRO 29 -77.74 -161.80 3 A GLU 4 -163.82 29.84 3 A GLN 5 -46.41 163.01 3 A SER 9 -108.97 -144.68 3 A CYS 11 -108.04 -168.31 3 A CYS 20 -55.86 -173.83 3 B VAL 2 -94.51 -159.55 3 B ASN 3 51.18 80.62 3 B GLU 21 173.27 -49.52 3 B PHE 24 -177.87 118.01 3 B THR 27 -154.69 17.59 3 B LYS 28 72.06 65.26 4 A GLU 4 163.34 160.20 4 A CYS 6 161.51 -23.34 4 A THR 8 83.45 1.70 4 A SER 9 -116.07 -141.52 4 A ILE 10 -145.72 -42.67 4 A CYS 11 39.95 -167.32 4 A CYS 20 -67.21 -174.56 4 B VAL 2 -92.63 -159.73 4 B LEU 6 -118.80 -165.13 4 B CYS 7 173.57 -54.87 4 B CYS 19 -93.76 -67.33 4 B GLU 21 172.27 96.89 4 B ARG 22 177.55 -34.01 4 B PRO 29 -78.68 -87.69 5 A GLU 4 -133.18 -153.18 5 A CYS 7 -76.12 -74.42 5 A CYS 11 -166.99 -168.66 5 B VAL 2 -80.14 -152.47 5 B ASN 3 -30.77 115.33 5 B SER 9 -39.26 -36.33 5 B ARG 22 174.05 -31.69 6 A GLU 4 -171.50 70.95 6 A SER 9 -91.73 -147.72 6 A ILE 10 -132.35 -34.32 6 A CYS 11 66.21 -161.30 6 B VAL 2 -160.26 -163.27 6 B ASN 3 -65.40 94.67 6 B CYS 7 -143.83 -39.38 6 B CYS 19 -98.56 -68.90 6 B ARG 22 -173.23 -36.71 6 B PHE 24 177.16 155.27 6 B PHE 25 -139.80 -79.75 6 B TYR 26 50.03 177.45 6 B LYS 28 53.05 106.90 6 B PRO 29 -77.50 -162.79 7 A CYS 6 56.84 16.43 7 A SER 9 -102.75 -168.32 7 A CYS 11 38.23 -164.73 7 A CYS 20 -69.57 -171.62 7 B VAL 2 -144.46 -151.13 7 B CYS 7 -146.48 -47.65 7 B ARG 22 174.13 -32.40 7 B LYS 28 -169.11 -61.44 8 A GLN 5 78.55 -71.43 8 A CYS 6 -150.47 32.14 8 A SER 9 -147.88 -157.16 8 A CYS 20 -68.13 -171.42 8 B VAL 2 -108.40 -160.65 8 B ASN 3 -45.70 161.60 8 B CYS 19 -75.87 -70.67 8 B GLU 21 -172.24 -90.08 8 B THR 27 -160.02 94.35 8 B LYS 28 64.11 110.75 8 B PRO 29 -78.64 -165.50 9 A GLU 4 -175.37 -67.15 9 A GLN 5 68.20 -72.32 9 A CYS 6 -147.37 29.29 9 A CYS 11 52.22 -177.24 9 B VAL 2 -160.83 -166.79 9 B GLU 21 175.99 -64.47 9 B PHE 24 165.44 144.04 9 B PHE 25 -140.30 -97.38 9 B TYR 26 55.91 94.59 9 B LYS 28 169.80 133.34 10 A GLU 4 59.97 119.92 10 A GLN 5 -150.60 -44.81 10 A CYS 6 -158.92 38.72 10 A SER 9 -121.99 -147.70 10 A ILE 10 -128.48 -63.28 10 A CYS 11 66.70 179.13 10 B VAL 2 -100.18 -159.45 10 B GLN 4 -105.13 53.03 10 B SER 9 -46.42 -75.16 10 B CYS 19 -101.69 -66.00 10 B GLU 21 156.62 52.98 10 B ARG 22 -146.76 13.17 10 B PRO 29 -76.59 -82.47 11 A GLU 4 177.37 145.68 11 A CYS 11 50.44 -170.74 11 A CYS 20 -104.45 -167.44 11 B CYS 7 -143.39 -39.06 11 B GLU 21 175.53 -68.76 11 B PHE 24 157.42 131.40 12 A SER 9 -104.23 -151.40 12 B ASN 3 63.50 110.54 12 B SER 9 -39.63 -75.08 12 B ARG 22 -172.57 -34.23 12 B PHE 24 -177.91 128.09 12 B TYR 26 165.04 111.08 12 B THR 27 -131.47 -147.98 12 B PRO 29 -77.17 -93.05 13 A GLU 4 -98.25 -90.64 13 A GLN 5 -131.30 -86.41 13 A CYS 7 -116.28 -71.56 13 A CYS 11 -109.85 -164.85 13 A CYS 20 -107.18 -165.64 13 B GLU 21 58.54 108.65 13 B ARG 22 158.27 -25.28 13 B PHE 24 42.08 91.07 13 B THR 27 -106.92 -145.82 13 B PRO 29 -78.96 -166.22 14 A GLU 4 -147.91 19.85 14 A CYS 6 -162.56 35.69 14 A SER 9 -123.86 -128.10 14 A CYS 20 -70.39 -167.37 14 B CYS 7 -121.60 -158.59 14 B CYS 19 -96.98 -61.68 14 B GLU 21 178.89 -56.91 14 B PHE 24 58.36 117.24 14 B LYS 28 172.40 -49.46 15 A GLU 4 179.52 40.53 15 A SER 9 -102.28 -150.27 15 A ILE 10 -132.19 -31.47 15 A CYS 11 56.70 -174.89 15 A CYS 20 -61.27 -168.10 15 B ASN 3 33.80 71.35 15 B CYS 7 -140.63 -44.92 15 B CYS 19 -88.70 -70.61 15 B GLU 21 -176.25 -76.42 15 B PHE 24 165.51 141.19 16 A GLU 4 -93.62 -66.97 16 A GLN 5 80.38 -13.46 16 A CYS 7 -130.77 -36.43 16 A THR 8 -76.20 -80.26 16 A SER 9 -72.51 -133.00 16 A CYS 11 -48.81 -177.94 16 B ASN 3 160.11 -159.70 16 B GLN 4 -77.83 -163.72 16 B CYS 7 -150.90 12.36 16 B ARG 22 171.67 -33.99 16 B PHE 24 -170.66 113.56 16 B LYS 28 164.61 -49.71 16 B PRO 29 -76.08 -93.50 17 A SER 9 -67.73 -157.63 17 A CYS 11 -59.88 -152.96 17 B VAL 2 -152.13 -151.17 17 B ASN 3 -147.87 55.34 17 B GLU 21 54.43 105.75 17 B ARG 22 175.09 -29.61 17 B THR 27 -152.66 -135.37 17 B PRO 29 -78.07 -85.59 18 A GLN 5 -159.72 -96.44 18 A THR 8 47.73 24.75 18 A SER 9 -151.98 -147.76 18 A ILE 10 -140.59 -49.96 18 A CYS 11 45.15 -175.43 18 B VAL 2 -134.63 -159.85 18 B GLU 21 175.37 -35.29 18 B TYR 26 177.24 168.44 18 B THR 27 -108.48 -102.02 18 B LYS 28 -169.87 100.15 19 A GLU 4 -137.41 -90.08 19 A GLN 5 81.44 -47.41 19 A CYS 7 -102.36 -66.55 19 A CYS 11 38.24 -165.27 19 B VAL 2 -161.46 -152.51 19 B ASN 3 -36.75 135.46 19 B GLU 21 -119.77 64.58 19 B PHE 24 -38.38 140.53 20 A CYS 20 -100.58 -165.56 20 B VAL 2 -118.41 -159.88 20 B CYS 19 -102.69 -63.67 20 B ARG 22 165.91 -34.14 NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE-A2-GLY, VAL-A3-GLY, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 20 STRUCTURES 1 N N 2 N N A LEU 13 A LEU 13 HELX_P A TYR 19 A TYR 19 1 1 7 B SER 9 B SER 9 HELX_P B CYS 19 B CYS 19 1 2 11 disulf 2.020 A CYS 6 A SG CYS 6 1_555 A CYS 11 A SG CYS 11 1_555 disulf 2.020 A CYS 7 A SG CYS 7 1_555 B CYS 7 B SG CYS 7 1_555 disulf 2.018 A CYS 20 A SG CYS 20 1_555 B CYS 19 B SG CYS 19 1_555 HORMONE/GROWTH FACTOR HORMONE, HUMAN INSULIN, MUTANT, HORMONE-GROWTH FACTOR COMPLEX INS_HUMAN UNP 1 90 P01308 GIVEQCCTSICSLYQLENYCN INS_HUMAN UNP 2 25 P01308 FVNQHLCGSHLVEALYLVCGERGFFYTPKT 90 110 1LKQ 1 21 P01308 A 1 1 21 25 54 1LKQ 1 30 P01308 B 2 1 30 1 ILE engineered mutation GLY 2 1LKQ A P01308 UNP 91 2 1 VAL engineered mutation GLY 3 1LKQ A P01308 UNP 92 3 2 HIS engineered mutation ASP 10 1LKQ B P01308 UNP 34 10 2 PRO engineered mutation LYS 28 1LKQ B P01308 UNP 52 28 2 LYS engineered mutation PRO 29 1LKQ B P01308 UNP 53 29 1 P 1